Interfering vaccine: A novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3018-3025

  Noble, Simon ^a   McLain, Lesley ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Defective interfering virus; Defective RNA; Influenza A virus; Interfering vaccine; Mice; Protection; Vaccine

Indexed keywords

HEMAGGLUTININ; SIALIDASE; VIRUS RNA; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; INFLUENZA; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RNA INTERFERENCE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BODY WEIGHT; CROSS REACTIONS; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED C3H; ORTHOMYXOVIRIDAE INFECTIONS; RNA, VIRAL; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 3843059126     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.013     Document Type: Article

References (39)

1. Webster R.G. Influenza virus: transmission between species and relevance to emergence of the next human pandemic. Arch. Virol. Suppl. 13:1997;105-113
2. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 279:1998;393-396
3. Centers for Disease Control and Prevention. Update: isolation of avian influenza A (H5N1) viruses from humans - Hong Kong, 1997-1998. MMWR 46;1998:1245-7.
4. Pieris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L.S., Lai R.W.M., et al. Human infection with influenza H9N2. Lancet. 354:1999;916-917
5. Guo Y.J., Krauss S., Senne D.H., Mo I.P., Lo K.S., Xiong X.P., et al. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Hong Kong. Virology. 267:2000;279-288
6. Saito T., Lim W., Suzuki T., Suzuki Y., Kida H., Nishimura S.-I., et al. Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine. 20:2001;125-133
7. Uyeki T.M., Chong Y.-H., Katz J., Lim W., Ho Y-Y., Wang S.S., et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China, 1999. Emerg. Infect. Dis. 8:2002;152-159
8. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8:1990;737-771
9. Webster R.G. Immunity to influenza in the elderly. Vaccine. 18:2000;1686-1689
10. Belshe R.B., Couch R.B., Glezen W.P., Treanor J.J. Live attenuated intranasal influenza vaccine. Vaccine. 20:2002;3429-3430
11. Hayden F.G., Couch R.B. Clinical and epidemiological importance of influenza viruses resistant to amantadine and rimantadine. Rev. Med. Virol. 2:1992;89-106
12. Cox N.J., Subbarao K. Influenza. Lancet. 354:1999;1277-1282
13. Fiddian A.P. Antiviral developments: progress with neuraminidase inhibitors. Rev. Med. Virol. 10:2000;135-137
14. Cox N.J. Panel summary of international pandemic influenza plans. J. Infect. Dis. 176(Suppl. 1):1997;S87-S88
15. Laver G., Garman E. The origin and control of pandemic influenza. Science. 293:2001;1776-1777
16. Rimmelzwaan G.F., Osterhaus A.D.M.E. Influenza vaccines: new developments. Curr. Opin. Pharmacol. 1:2001;491-496
17. Webster R.G., Walker E.J. Influenza - the world is teetering on the edge of a pandemic that could kill a large fraction of the human population. Am. Scientist. 91:2003;122-129
18. Huang A.S., Baltimore D. Defective viral particles and viral disease processes. Nature (Lond.). 226:1970;325-327
19. Barrett A.D.T., Dimmock N.J. Defective interfering viruses and infections of animals. Curr. Topics Microbiol. Immunol. 128:1986;55-84
20. Dimmock NJ. Antiviral activity of defective interfering influenza virus in vivo. In: Myint S, Taylor-Robinson D., editors. Viral and other infections of the respiratory tract. London: Chapman and Hall, 1996; p. 421-445.
21. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM., editors. Fields virology, vol. 1. 3rd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996. p. 1353-95.
22. Duhaut S.D., Dimmock N.J. Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology. 248:1998;241-253
23. Dimmock N.J., Beck S., McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J. Gen. Virol. 67:1986;839-850
24. Noble S., Dimmock N.J. Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus. J. Gen. Virol. 75:1994;3485-3491
25. Morgan D.J., McLain L., Dimmock N.J. Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res. 29:1993;179-193
26. Cane C., McLain L., Dimmock N.J. Intracellular stability of the interfering activity of a defective interfering influenza virus in the absence of virus multiplication. Virology. 159:1987;259-264
27. Duhaut S., McCauley J.W. Defective RNAs inhibit the assembly of influenza virus genome segments in a segment-specific manner. Virology. 216:1996;326-337
28. Duhaut S.D., Dimmock N.J. Defective segment 1 RNAs that interfere with the production of infectious influenza virus require at least 150 nucleotides of 5′ sequence: evidence from a plasmid-driven system. J. Gen. Virol. 83:2002;403-411
29. Schulman J.L. The role of antineuraminidase antibody in immunity to influenza virus infection. Bull. Wld. Hlth. Org. 41:1969;647-650
30. Chen Z., Kadowaki S.-E., Hagiwara Y., Yoshikawa T., Matsuo K., Kurata T., et al. Cross-protection against a lethal virus infection by DNA vaccine to neuraminidase. Vaccine. 18:2000;3214-3222
31. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.L., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1990;1375-1377
32. Neirynck S., Deroo T., Vanlandschoot P., Jou W.M., Fiers W. A universal vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1999;1157-1163
33. Duhaut S.D., Dimmock N.J. Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J. Virol. Meth. 108:2003;75-82
34. DePolo N., Giachetti C., Holland J.J. Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J. Virol. 61:1987;454-464
35. Huang A.S. Defective interfering viruses. Annu. Rev. Microbiol. 27:1973;101-117
36. Holland JJ, Kennedy SIT, Semler BL, Jones KL, Roux L, Grabau E. Defective interfering RNA viruses and the host cell response. In: Fraenkel-Conrat H, Wagner RR, editors. Comprehensive virology, vol. 16. New York: Plenum Press; 1980. p. 137-92.
37. Perrault J. Origin and replication of defective interfering particles. Curr. Top. Microbiol. Immunol. 93:1981;151-207
38. Nayak DP, Chambers TM, Akkina RM. Structure of defective-interfering RNAs of influenza virus and their role in interference. In: Krug RM, editor. The influenza viruses. New York: Plenum Press; 1989. p. 269-317.
39. Dimmock N.J. The biological significance of defective interfering viruses. Rev. Med. Virol. 1:1991;165-176